 My name is C.K. Penn, and I'm the team leader of the Dynamical Biomarker Group from Taiwan. Taiwan has a universal healthcare system which covers about 99.9% of the population. There has to be a way to reduce the cost. So that's the reason we actually, as a group, are very interested in this competition, because we are actually developing technology that can help the government to reduce their universal healthcare insurance costs. In Taiwan, a lot of problems will relate to liver problems. With this platform, we can actually include more and more technology, too, into those devices. You need to involve many different people, experts from different disciplines. So we have physicians, we have engineers, basic scientists, and user interface people who want to develop user-friendly interface. So all those people working together is a big challenge. Basically, there are sensors put on the body, like EKG, respiration, temperature, etc. And then they send to the smartphone. The smartphone will do some using the algorithm we developed to identify certain types of disease. There's a lot of people who need very basic medical care, and you don't need to do very fancy technology, but some very basic technology that people can use at home. Our technology combines the thinking of Western medicine, but we also have the more traditional Chinese medicine, we are thinking that the system is a complex system, it's constantly changing, moving. From that consideration, I think the investment into this new market, which is not existing at this point, is actually a very good investment.